Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010415 | 0.87 | KDM1A (0.41) | KDM1AKDM1BGPR84 | |
| SCHEMBL8052822 | 0.87 | KDM1A (0.41) | KDM1AKDM1BGPR84 | |
| SCHEMBL2151812 | 0.82 | KDM1A (0.45) | KDM1AKDM1BGPR84 | |
| SCHEMBL7597819 | 0.80 | IDO1 (0.36) | IDO1 | |
| SCHEMBL10741517 | 0.79 | KDM1A (0.33) | KDM1AKDM1BGPR84POLBAPEX1 | |
| SCHEMBL29537970 | 0.78 | DPP4 (0.41) | DPP4 | |
| SCHEMBL724623 | 0.78 | DPP4 (0.41) | DPP4 | |
| SCHEMBL11554562 | 0.77 | DPP4 (0.34) | DPP4IDO1 | |
| SCHEMBL3824032 | 0.77 | POLB (0.33) | KDM1AKDM1BGPR84POLBAPEX1 | |
| SCHEMBL30030017 | 0.77 | DPP4 (0.33) | KDM1AKDM1BGPR84DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | KDM1A 3929/4885KDM1B 4112/4885GPR84 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.